Ignite Creation Date:
2024-05-05 @ 7:03 PM
Last Modification Date:
2024-10-26 @ 9:41 AM
Study NCT ID:
NCT00590824
Status:
COMPLETED
Last Update Posted:
2019-11-21
First Post:
2007-12-19
Brief Title:
Pilot hu1418-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
A Pilot Trial of HU1418-IL2 EMD273063 in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the antitumor activity of hu1418-IL2 in the minimal residual disease setting Evaluate the time to recurrence and overall survival of patients treated with hu1418-IL2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01CA032685 | NIH | UW Madison | httpsreporternihgovquickSearchR01CA032685 |
| CO05601 | None | None | None |
| 2013-1224 | REGISTRY | None | None |
| NCI-2009-00276 | REGISTRY | None | None |
| A536755 | OTHER | None | None |
| SMPHPEDIATRICSPEDIATRICS | OTHER | None | None |